Medcura
- Company typePrivate
- Founded2019
- HeadquartersRiverdale, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
Medcura firmographics
Firmographics- Name
- Medcura
- Legal name
- Medcura, Inc.
- Website
- https://medcurainc.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Medcura industry classification
Industry- Product category
- Surgical Hemostasis / Wound Care Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- First Aid & Wound Care (Bandages, Dressings, Antiseptics, Burn Care) (CRADAMAB)
Keywords
Where Medcura is headquartered
LocationHeadquarters
- HQ city
- Riverdale
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Medcura business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Surgical Hemostatic Products: Revenue from sale of FDA-cleared and developmental surgical hemostatic products including LifeGel, LifeFoam, LifeCoat, LifePatch, LifeFilm, and LifePutty for use in spine surgery, cardiac surgery, and trauma applications.
- Consumer Wound Care Products: Revenue from over-the-counter consumer products including Rapid-Seal wound management gel sold through major retail chains (CVS, Walgreens, Walmart.com, Amazon) and Seal-It pet wound care gel.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Medcura product offering
Product offeringCore offering
Medcura develops and manufactures a portfolio of hemostatic products based on a proprietary hydrophobically modified chitosan biopolymer platform, including LifeGel (FDA Breakthrough Device Designated surgical gel), LifeFoam, LifeCoat, LifePatch, LifeFilm, and LifePutty for surgical bleeding control in spine, cardiac, trauma, and minimally invasive procedures. The company also sells consumer wound care products (Rapid-Seal) and pet wound care gel (Seal-It) through major retail and e-commerce channels.
Product overview
Medcura is a medical device company developing a comprehensive LIFE™ Surgical Hemostasis Portfolio of hemostatic products based on a proprietary hydrophobically modified chitosan biopolymer platform. The flagship product is LifeGel™, the first and only absorbable hemostatic agent with FDA Breakthrough Device Designation for its no-swell properties, targeting the $2.5 billion global surgical hemostasis market with initial focus on spine surgery. The portfolio includes multiple product formats—gel (LifeGel), foam (LifeFoam), powder (LifeCoat), patch (LifePatch), film (LifeFilm), putty (LifePutty), sheet (LifeSheet), and fiber (LifeFib)—designed to address bleeding control across surgical, military/trauma, and consumer applications. The company also offers consumer products including Rapid-Seal™ wound management gel and Seal-It™ pet wound care gel sold through major retail channels. The company has received five FDA clearances (K172010, K143466, K192667, K182811, K180152) and two FDA Breakthrough Device Designations.
Differentiator
Problem solved
Functional benefit
Brands
- LifeGel: Lead product - FDA Breakthrough Device Designated absorbable hemostatic gel for surgical bleeding control, particularly in spine surgery applications.
- LifeFoam
- LifeCoat
- LifePatch
- LifeFilm
- LifePutty
- LIFE Surgical Hemostasis Portfolio
- Rapid-Seal
- Seal-It
Products and services
- LifeGel Flagship flowable absorbable hemostatic gel designed to control surgical bleeding without swelling, specifically developed for spinal surgery and other procedures where swelling cannot be tolerated. The first and only absorbable hemostatic agent to receive FDA Breakthrough Device Designation.
- LifeFoam Ready-to-use expanding hemostatic foam in syringe or spray form composed of modified chitosan designed to stop bleeding during trauma, orthopedic and plastic surgery scenarios. Targets severe traumatic bleeding and non-compressible injuries; received FDA Breakthrough Device Designation for traumatic wounds.
- LifeCoat Hemostatic powder delivered by bellows applicator during surgical procedures for minimal, mild, and moderate surgical bleeding. Positioned against existing absorbable hemostatic powders which are expensive and not designed for moderate surgical bleeding.
- LifePatch
- LifeFilm
- LifePutty
- LifeSheet
- LifeFib
- Rapid-Seal
- Seal-It
Quantifiable outcome
- Resorbs in approximately 8-12 weeks after application
- +2 more outcomes
Companies that use Medcura
Customer profileNamed customers6 records
Segments5 records
Ideal customer profiles5 records
Medcura technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Medcura partnerships and signals
Strategic signalScale indicators10 records
Recent moves8 records
Expansion highlights6 records
Medcura competitors and assessment
Company assessmentBroad incumbents
- Becton Dickinson (BD): BD manufactures a broad portfolio of surgical hemostats and wound care products across its medical device segment. Its scale, sales infrastructure, and hospital relationships make it a significant competitor and potential strategic acquirer in the surgical hemostasis space.
- Ethicon (Johnson & Johnson): Ethicon manufactures the Surgicel, Surgiflo, and Evicel lines of surgical hemostats and sealants under the J&J MedTech umbrella. As the dominant surgical hemostat franchise globally, Surgiflo and Surgicel powder are the most direct competitors to Medcura's LifeGel and LifeCoat.
- CSL Behring: CSL Behring (CSL Limited subsidiary) markets fibrin sealant and other plasma-derived hemostatic products for surgical applications. Its biological hemostat portfolio and global hospital reach position it as an incumbent in the broader surgical bleeding control market.
- Pfizer (GelFoam franchise): Pfizer manufactures GelFoam absorbable gelatin sponge and powder, one of the oldest and most widely used surgical hemostat brands. GelFoam is explicitly cited on Medcura's website as a swelling competitor that LifeGel is positioned against.
Emerging players
- Arch Therapeutics: Arch Therapeutics is a clinical-stage medical device company developing AC5, a self-assembling peptide hemostatic technology for surgical and trauma applications. It represents the closest emerging-stage analog to Medcura's clinical pathway and Breakthrough Designation strategy.
- Cohera Medical: Cohera Medical develops surgical adhesives and sealants (Sylys, TissuGlu) used in post-surgical applications. While focused on sealants rather than hemostats, the company's surgical specialty overlap and emerging commercial stage make it a comparable emerging medical device peer.
Direct peers
- Baxter International: Baxter markets FloSeal Hemostatic Matrix, the dominant flowable surgical hemostat globally. Medcura's SVP Steve Ford previously grew FloSeal to $350M+ in sales, and Medcura's lead product LifeGel is positioned as a direct non-swelling alternative to FloSeal.
- Integra LifeSciences: Integra offers a portfolio of surgical hemostats, dural sealants, and neurosurgical products that compete across multiple of Medcura's target segments including spine and neurosurgery. The company also provides regenerative tissue technologies relevant to orthopedic hemostasis.
- Biom'Up: Biom'Up developed HEMOBLAST Bellows, a surgical hemostatic powder delivered via bellows applicator that competes with Medcura's LifeCoat powder. Medcura's commercial advisor Dave Clark previously co-led the U.S. launch of HEMOBLAST at Biom'Up.
- CryoLife: CryoLife (now Artivion) markets BioGlue and other surgical hemostats/sealants used in cardiac and vascular surgery—directly overlapping with Medcura's cardiac surgery use cases for LifeGel and LifeFilm.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Medcura social profiles
Digital presenceMedcura compliance and trust
Trust signalCompliance7 records
Medcura financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medcura leadership team
Management profileNumber of profiles
Profiles15 records
Medcura funding detail
Funding detailFunding overview
Funding rounds10 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medcura M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medcura
What does Medcura do?
Medcura develops and manufactures a portfolio of hemostatic products based on a proprietary hydrophobically modified chitosan biopolymer platform, including LifeGel (FDA Breakthrough Device Designated surgical gel), LifeFoam, LifeCoat, LifePatch, LifeFilm, and LifePutty for surgical bleeding control in spine, cardiac, trauma, and minimally invasive procedures. The company also sells consumer wound care products (Rapid-Seal) and pet wound care gel (Seal-It) through major retail and e-commerce channels.
Is Medcura a public or private company?
Medcura is a private company. It is classified as venture growth investor backed and is currently operating.
When was Medcura founded?
Medcura was founded in 2019. It employs 11 to 50 people.
Where is Medcura based?
Medcura is headquartered in Riverdale, United States, in the North America region.
How does Medcura make money?
Two revenue lines are on record. Surgical Hemostatic Products are the primary driver. The others are consumer Wound Care Products.
Who are Medcura's main competitors?
Broad incumbents on record are Becton Dickinson (BD), Ethicon (Johnson & Johnson), CSL Behring and Pfizer (GelFoam franchise). Emerging players are Arch Therapeutics and Cohera Medical. Direct peers are Baxter International, Integra LifeSciences, Biom'Up and CryoLife.
Does Medcura have an API?
No public API is recorded for Medcura.
What industry is Medcura in?
Medcura's product category is Surgical Hemostasis / Wound Care Medical Devices. Its primary akta.pro industry code is CRADAMAB, First Aid & Wound Care (Bandages, Dressings, Antiseptics, Burn Care). Its NAICS code is 339113 and its SIC code is 3841.